文献速递肝病

肝细胞ELOVL6决定神经酰胺酰基链长度及小鼠肝脏胰岛素敏感性

Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice.
PubMed 文献 · Hepatology · 2020-02-07

研究通过肝特异性Elovl6敲除小鼠探讨肝脏ELOVL6对能量稳态的影响。LKO小鼠在高脂饮食下未受保护,但在高蔗糖饮食下胰岛素敏感性增强,与肝脏神经酰胺(d18:1/18:0)降低及Pnpla3下调有关。在ob/ob小鼠中肝脏Elovl6缺失同样改善胰岛素抵抗。

要点

  • 肝Elovl6缺失在高蔗糖饮食而非高脂饮食下增强胰岛素敏感性
  • 神经酰胺(d18:1/18:0)通过PP2A-Akt轴负向调控肝脏胰岛素信号
  • Pnpla3参与Elovl6缺失导致的胰岛素敏感性改善

核心结论

  • 肝脏Elovl6通过调控神经酰胺酰基链组成影响肝脏胰岛素信号,C18:0-神经酰胺是肝脏胰岛素信号的有效调节因子并与Pnpla3介导的NAFLD相关。

研究设计与样本

  • 研究构建了肝特异性Elovl6敲除(LKO)小鼠,并在高脂饮食、高蔗糖饮食及ob/ob小鼠背景下评估胰岛素敏感性。
  • 采用脂质组学分析肝脏神经酰胺含量,并通过腺病毒恢复Pnpla3表达进行机制验证。

主要发现

  • LKO小鼠在高脂饮食诱导的胰岛素抵抗中未受保护。
  • LKO小鼠在高蔗糖饮食下胰岛素敏感性高于对照组。
  • LKO小鼠肝脏Pnpla3表达下调,腺病毒恢复Pnpla3可逆转高蔗糖饮食下LKO小鼠的胰岛素敏感性增强。
  • LKO小鼠肝脏神经酰胺(d18:1/18:0)含量降低。
  • 神经酰胺(d18:1/18:0)通过干扰PP2A与PP2A抑制因子2的结合增强PP2A活性,导致Akt去磷酸化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Dysfunctional hepatic lipid metabolism is a cause of nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, and is closely associated with insulin resistance and type 2 diabetes. ELOVL fatty acid elongase 6 (Elovl6) is responsible for converting C16 saturated and monounsaturated fatty acids (FAs) into C18 species. We have previously shown that Elovl6 contributes to obesity-induced insulin resistance by modifying hepatic C16/C18-related FA composition. APPROACH AND RESULTS: To define the precise molecular mechanism by which hepatic Elovl6 affects energy homeostasis and metabolic disease, we generated liver-specific Elovl6 knockout (LKO) mice. Unexpectedly, LKO mice were not protected from high-fat diet-induced insulin resistance. Instead, LKO mice exhibited higher insulin sensitivity than controls when consuming a high-sucrose diet (HSD), which induces lipogenesis. Hepatic patatin-like phospholipase domain-containing protein 3 (Pnpla3) expression was down-regulated in LKO mice, and adenoviral Pnpla3 restoration reversed the enhancement in insulin sensitivity in HSD-fed LKO mice. Lipidomic analyses showed that the hepatic ceramide(d18:1/18:0) content was lower in LKO mice, which may explain the effect on insulin sensitivity. Ceramide(d18:1/18:0) enhances protein phosphatase 2A (PP2A) activity by interfering with the binding of PP2A to inhibitor 2 of PP2A, leading to Akt dephosphorylation. Its production involves the formation of an Elovl6-ceramide synthase 4 (CerS4) complex in the endoplasmic reticulum and a Pnpla3-CerS4 complex on lipid droplets. Consistent with this, liver-specific Elovl6 deletion in ob/ob mice reduced both hepatic ceramide(d18:1/18:0) and PP2A activity and ameliorated insulin resistance. CONCLUSIONS: Our study demonstrates the key role of hepatic Elovl6 in the regulation of the acyl-chain composition of ceramide and that C18:0-ceramide is a potent regulator of hepatic insulin signaling linked to Pnpla3-mediated NAFLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Matsuzaka T, Kuba M, Koyasu S, et al. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice. Hepatology. 2020. PMID: 31529722. doi:10.1002/hep.30953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。